JP2013516457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516457A5 JP2013516457A5 JP2012547588A JP2012547588A JP2013516457A5 JP 2013516457 A5 JP2013516457 A5 JP 2013516457A5 JP 2012547588 A JP2012547588 A JP 2012547588A JP 2012547588 A JP2012547588 A JP 2012547588A JP 2013516457 A5 JP2013516457 A5 JP 2013516457A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- inflammatory
- pharmaceutical composition
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002757 inflammatory effect Effects 0.000 claims description 53
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 45
- 208000027866 inflammatory disease Diseases 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 22
- 230000004043 responsiveness Effects 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 5
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 5
- 239000000090 biomarker Substances 0.000 claims description 5
- 229960003776 glatiramer acetate Drugs 0.000 claims description 5
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 4
- 229960005370 atorvastatin Drugs 0.000 claims description 4
- 208000010643 digestive system disease Diseases 0.000 claims description 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 4
- 229960002855 simvastatin Drugs 0.000 claims description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 4
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003765 fluvastatin Drugs 0.000 claims description 3
- 229960004844 lovastatin Drugs 0.000 claims description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002965 pravastatin Drugs 0.000 claims description 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 108010065805 Interleukin-12 Proteins 0.000 claims 3
- 102000013462 Interleukin-12 Human genes 0.000 claims 3
- 208000025865 Ulcer Diseases 0.000 claims 3
- 231100000397 ulcer Toxicity 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- -1 IL-Iβ Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 230000005784 autoimmunity Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 229960000301 factor viii Drugs 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000002956 necrotizing effect Effects 0.000 claims 2
- 208000037804 stenosis Diseases 0.000 claims 2
- 230000036262 stenosis Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 1
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000013600 Diabetic vascular disease Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010017711 Gangrene Diseases 0.000 claims 1
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000013691 Interleukin-17 Human genes 0.000 claims 1
- 108050003558 Interleukin-17 Proteins 0.000 claims 1
- 102100030703 Interleukin-22 Human genes 0.000 claims 1
- 102000013264 Interleukin-23 Human genes 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 206010030201 Oesophageal ulcer Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 208000028299 esophageal disease Diseases 0.000 claims 1
- 208000019064 esophageal ulcer Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 108010074109 interleukin-22 Proteins 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000023569 ischemic bowel disease Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000002385 vertebral artery Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 62
- 239000013543 active substance Substances 0.000 description 18
- 230000002411 adverse Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 229960000672 rosuvastatin Drugs 0.000 description 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29222610P | 2010-01-05 | 2010-01-05 | |
| US61/292,226 | 2010-01-05 | ||
| US28225010P | 2010-01-07 | 2010-01-07 | |
| US61/282,250 | 2010-01-07 | ||
| US35197510P | 2010-06-07 | 2010-06-07 | |
| US61/351,975 | 2010-06-07 | ||
| US38931810P | 2010-10-04 | 2010-10-04 | |
| US61/389,318 | 2010-10-04 | ||
| US42311210P | 2010-12-15 | 2010-12-15 | |
| US61/423,112 | 2010-12-15 | ||
| PCT/IL2011/000010 WO2011083467A1 (en) | 2010-01-05 | 2011-01-05 | Combined treatment utilizing vb-201 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013516457A JP2013516457A (ja) | 2013-05-13 |
| JP2013516457A5 true JP2013516457A5 (enExample) | 2014-02-20 |
Family
ID=44305239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547588A Pending JP2013516457A (ja) | 2010-01-05 | 2011-01-05 | Ｖｂ−２０１を用いた併用治療法 |
| JP2012547586A Pending JP2013516455A (ja) | 2010-01-05 | 2011-01-05 | Ｖｂ−２０１を用いた治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547586A Pending JP2013516455A (ja) | 2010-01-05 | 2011-01-05 | Ｖｂ−２０１を用いた治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20120329758A1 (enExample) |
| EP (2) | EP2521454A4 (enExample) |
| JP (2) | JP2013516457A (enExample) |
| KR (1) | KR20120133375A (enExample) |
| CN (1) | CN102834011B (enExample) |
| AU (1) | AU2011204406B2 (enExample) |
| BR (1) | BR112012016543A2 (enExample) |
| CA (1) | CA2786060A1 (enExample) |
| ES (1) | ES2654944T3 (enExample) |
| MX (1) | MX2012007807A (enExample) |
| NZ (1) | NZ601224A (enExample) |
| WO (3) | WO2011083469A1 (enExample) |
| ZA (1) | ZA201205425B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| US7807847B2 (en) | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
| US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
| US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
| EP2348864A4 (en) * | 2008-10-08 | 2013-07-31 | Vascular Biogenics Ltd | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF |
| EP2826370A3 (en) | 2008-11-06 | 2015-04-08 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
| CA2847218C (en) * | 2011-09-01 | 2018-02-27 | Vascular Biogenics Ltd. | Formulations and dosage forms of oxidized phospholipids |
| ES2758923T3 (es) * | 2011-12-12 | 2020-05-07 | Vascular Biogenics Ltd | Tratamiento de esteatohepatitis no alcohólica |
| EP2814497A4 (en) * | 2012-02-16 | 2015-12-09 | Vascular Biogenics Ltd | METHOD FOR TREATING PSORIASIS AND VESSEL IGNITION |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| EP3223824B1 (en) | 2014-11-26 | 2021-01-06 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| WO2017173203A1 (en) * | 2016-03-31 | 2017-10-05 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing intestinal permeability |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| WO2002041827A2 (en) * | 2000-11-24 | 2002-05-30 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| PL1773352T3 (pl) * | 2004-07-09 | 2014-04-30 | Vascular Biogenics Ltd | Ulepszony sposób wytwarzania utlenionych fosfolipidów |
| US8084209B2 (en) * | 2005-07-22 | 2011-12-27 | Children's Hospital & Research Center Oakland | HMGCR isoforms in prediction of efficacy and identification of cholesterol-modulating compounds |
| US20090074720A1 (en) * | 2005-10-28 | 2009-03-19 | Sabbadini Roger A | Methods for decreasing immune response and treating immune conditions |
| US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| CA2702437C (en) * | 2007-11-28 | 2013-06-25 | Teva Pharmaceutical Industries Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
-
2011
- 2011-01-05 JP JP2012547588A patent/JP2013516457A/ja active Pending
- 2011-01-05 CA CA2786060A patent/CA2786060A1/en not_active Abandoned
- 2011-01-05 CN CN201180009408.XA patent/CN102834011B/zh not_active Expired - Fee Related
- 2011-01-05 ES ES11731736.2T patent/ES2654944T3/es active Active
- 2011-01-05 AU AU2011204406A patent/AU2011204406B2/en not_active Ceased
- 2011-01-05 WO PCT/IL2011/000012 patent/WO2011083469A1/en not_active Ceased
- 2011-01-05 BR BRBR112012016543-7A patent/BR112012016543A2/pt not_active IP Right Cessation
- 2011-01-05 WO PCT/IL2011/000010 patent/WO2011083467A1/en not_active Ceased
- 2011-01-05 EP EP11731734.7A patent/EP2521454A4/en not_active Withdrawn
- 2011-01-05 KR KR1020127020564A patent/KR20120133375A/ko not_active Withdrawn
- 2011-01-05 US US13/520,713 patent/US20120329758A1/en not_active Abandoned
- 2011-01-05 NZ NZ60122411A patent/NZ601224A/en not_active IP Right Cessation
- 2011-01-05 US US13/520,719 patent/US20130172294A1/en not_active Abandoned
- 2011-01-05 WO PCT/IL2011/000008 patent/WO2011083465A1/en not_active Ceased
- 2011-01-05 MX MX2012007807A patent/MX2012007807A/es not_active Application Discontinuation
- 2011-01-05 JP JP2012547586A patent/JP2013516455A/ja active Pending
- 2011-01-05 EP EP11731736.2A patent/EP2521569B1/en active Active
-
2012
- 2012-07-19 ZA ZA2012/05425A patent/ZA201205425B/en unknown
-
2013
- 2013-03-14 US US13/828,643 patent/US20130225525A1/en not_active Abandoned
-
2015
- 2015-02-13 US US14/622,093 patent/US20160008381A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516457A5 (enExample) | ||
| US10709678B2 (en) | Methods of reducing risk of cardiovascular disease | |
| Husain et al. | Inflammation, oxidative stress and renin angiotensin system in atherosclerosis | |
| Kiyosue et al. | A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk | |
| JP2019048843A5 (enExample) | ||
| EP2521569B1 (en) | Combined treatment utilizing vb-201 | |
| US9168308B2 (en) | Compositions and methods for nutritional supplementation | |
| MA28215A1 (fr) | Formes galeniques de l'oxycodone à libération contrôlée pour administration orale une fois par jour | |
| JP2016517883A5 (enExample) | ||
| JP2013516455A5 (enExample) | ||
| IL294736A (en) | Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them | |
| CN117940125A (zh) | His弱应答者的治疗 | |
| HK1250484A1 (zh) | 用於治疗胰腺炎的吉卡宾和衍生物 | |
| Bakakos et al. | Statins and left ventricular function | |
| JP2007528369A5 (enExample) | ||
| KR101686881B1 (ko) | 스타틴을 포함하는 갑상선 안병증의 예방 또는 치료용 약제학적 조성물 | |
| KR101627045B1 (ko) | 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물 | |
| Hasegawa | Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy | |
| AU2015202580B2 (en) | Gemcabene and derivatives for treating pancreatitis | |
| Ballantyne et al. | 1084-176 Efficacy of ezetimibe coadministered with simvastatin versus atorvastatin in patients with hypercholesterolemia | |
| Srivastava et al. | STATINS-THE MOST CONTROVERSIAL DRUG OF OUR TIMES: A COMMENTARY | |
| Huijgen et al. | L6 EFFICACY OF 15 YEARS OF GENETIC CASCADE SCREENING FOR FAMILIAL HYPERCHOLESTEROLEMIA IN THE NETHERLANDS IN PREVENTION OF CORONARY ARTERY DISEASE | |
| CN102416015A (zh) | 一种含他汀类药物的组合物及其用途 | |
| Angersbach et al. | A randomised dosage increase in patients not responding to paroxetine and maprotiline | |
| Lupattelli et al. | Lipids and Endothelial Dysfunction |